Lupin Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States".
Lupin Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States".